Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance - Inspira Technologies Oxy (NASDAQ:IINN)

Core Insights - Inspira Technologies announced pivotal results for its HYLA blood sensor, achieving 97.35% accuracy in performance testing, which supports its upcoming FDA submission [1][6] - The HYLA sensor is designed for continuous, real-time monitoring of key blood parameters, addressing urgent needs in operating rooms and critical care [3][6] - The company is positioned to penetrate the broader disposables market with a planned razor-and-blade recurring revenue model [2][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its FDA-cleared INSPIRA™ ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [4] - The company is developing the next-generation INSPIRA ART500 system, which aims to deliver oxygenation while patients remain awake and spontaneously breathing [4] - Inspira Technologies has a growing IP portfolio and is strategically streamlining operations to align with long-term industry trends, including consolidation and potential strategic partnerships [4] Product Features - The HYLA Blood Sensor provides continuous monitoring, delivering second-by-second data without the need for intermittent blood draws [6] - It utilizes non-invasive optical measurement technology, making it versatile for various medical procedures, including cardiopulmonary bypass and dialysis [6] - The sensor's modular design is engineered to complement existing medical devices, targeting the two million annual open-heart surgery patients globally [6]